Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 5.96
+0.23 (3.93%)
Oct 21, 2026, 4:08 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 217 employees as of June 30, 2026. That makes Ascletis Pharma the 26,216th largest employer in the world and 1,669th in Hong Kong.
Employees
217
Change
n/a
Growth
n/a
Revenue / Employee
5.04K HKD
Profits / Employee
-3.15M HKD
Market Cap
6.29B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 217 | - | - |
| Dec 31, 2025 | 202 | -29 | -12.55% |
| Dec 31, 2024 | 231 | 12 | 5.48% |
| Dec 31, 2023 | 219 | -59 | -21.22% |
| Dec 31, 2022 | 278 | 12 | 4.51% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 1,999 |
| CK Life Sciences Int'l., (Holdings) | 1,925 |
| Lepu Biopharma | 646 |
| Alphamab Oncology | 515 |
| CARsgen Therapeutics Holdings | 424 |
| Abbisko Cayman | 286 |
| CStone Pharmaceuticals | 147 |
| LongBio Pharma (Suzhou) | 94 |
Ascletis Pharma News
- 1 day ago - Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity - PRNewsWire
- 19 days ago - Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026 - PRNewsWire
- 22 days ago - Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis - PRNewsWire
- 6 weeks ago - Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs - PRNewsWire
- 7 weeks ago - Ascletis Pharma Earnings release: H1 2026 - Filings
- 7 weeks ago - Ascletis Pharma Quarterly report: H1 2026 - Filings
- 7 weeks ago - Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management - PRNewsWire
- 2 months ago - Ascletis Pharma Slides: Corporate presentation - Filings